cas 1324003-62-4|| where to buy propan-2-yl 2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzene-1-sulfonate

Nom du produit:propan-2-yl 2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzene-1-sulfonate

IUPAC Name:propan-2-yl 2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzene-1-sulfonate

Unité d'emballage	Stock disponible	Prix($)	Quantité

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 1324003-62-4 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:1324003-62-4; Formule moléculaire:C15H23BO5S; Point de fusion:-; Code SMILES:CC(C)OS(=O)(=O)C1=C(C=CC=C1)B1OC(C)(C)C(C)(C)O1; Densité:

: Numéro de catalogue:CM1045561; Poids moléculaire:326.21; Point d'ébullition:; N° Mdl:; Stockage:

: Boronic Acids and Esters; Boronic acids and boronate esters are commonly used reagents in Suzuki–Miyaura coupling chemistry. Organoboron derivatives are common reagents for C–C bond formation, either through classical palladium-mediated transformations or through other newer coupling methods. Boronic esters and acids are potential intermediates in the manufacture of many active pharmaceutical ingredients (API).; Boronic Acid For Sale; Find trusted boronic acid for sale. Any requirements and problems can ask us at any time.

: Sparsentan; CSL Vifor and Travere Therapeutics announce European Commission approves FILSPARI(sparsentan) for the treatment of IgA Nephropathy (IgAN). First non-immunosuppressive therapy for the treatment of IgAN approved in Europe.
Sparsentan is a novel, non-immunosuppressive, single-molecule, dual endothelin angiotensin receptor antagonist with high selectivity for the endothelin A receptor (ETAR) and the angiotensin II subtype 1 receptor (AT1R). Pre-clinical data have shown that blockade of both endothelin type A and angiotensin II type 1 pathways in forms of rare chronic kidney disease, protects podocytes, prevents glomerulosclerosis and mesangial cell proliferation, and reduces proteinuria.